AC Immune to Present at the Jefferies 2025 London Healthcare Conference
Rhea-AI Summary
AC Immune (NASDAQ: ACIU) will participate in the Jefferies 2025 London Healthcare Conference, November 17-20, 2025.
Management will take part in a fireside chat on November 18, 2025 at 4:30 AM ET / 9:30 AM GMT and will hold one-on-one investor meetings. A live webcast of the fireside chat will be available on the company Events Page, and a replay will be archived there. Investors should contact their Jefferies representative to request meetings with management during the conference.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ACIU gained 1.19%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AC Immune to Present at the Jefferies 2025 London Healthcare Conference
Lausanne, Switzerland, November 11, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies Global Healthcare Conference in London, taking place November 17-20, 2025.
The fireside chat will take place on November 18, 2025, at 4:30 AM (ET) / 9:30 AM (GMT). A webcast of the fireside chat will be available on the Events Page of AC Immune’s website. A replay will be archived in the same location.
Please contact your Jefferies representative to request a meeting with AC Immune’s management team at the conference.
About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >
SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, EU, GB, JP, KR, NO, RU and SG.
The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.
For further information, please contact:
| SVP, Investor Relations & Corporate Communications Gary Waanders, Ph.D., MBA AC Immune Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com | |
| International Media Chris Maggos Cohesion Bureau Phone: +41 79 367 6254 Email: chris.maggos@cohesionbureau.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
Attachment
FAQ
When will AC Immune (ACIU) present at the Jefferies 2025 London Healthcare Conference?
How can I watch AC Immune's (ACIU) fireside chat on November 18, 2025?
How do I request a one-on-one meeting with AC Immune (ACIU) management at the Jefferies conference?
What topics will AC Immune (ACIU) management likely discuss at the November 18 fireside chat?
Will there be a replay if I miss AC Immune's (ACIU) live presentation on November 18, 2025?
